Opening stock page...
Fetching company snapshot, pricing, and intelligence.
Intelligence coverage: 65%
Basic profile, financials, and market data are shown below. Deep research is building in the background.
AI confidence 70% · prior close shown (market closed)
Royalty Pharma plc shows stable business momentum based on AlphaOS pipeline evidence.
Why it matters: Revenue +16% YoY in Q2 FY2026.
3 signals not yet derived from pipeline evidence
What it means for the thesis — synthesis, not a raw event feed.
Pipeline evidence · 22d ago
RPRX's AlphaOS Signals
Upgrade to Pro for validated historical pattern analysis on RPRX.
Free accounts see more of this; Premium sees all of it.
Reported figures for Royalty Pharma plc — research only, not investment advice.
Updated
What happened recently for Royalty Pharma plc (RPRX) — events, not interpretation.
Research & analysis only — not investment advice.
Held in ETFsweight · est. sleeve dollars
Investment snapshot
RPRX's AI investment thesis
Upgrade to Premium for RPRX's full multi-agent investment thesis.
Free accounts see more of this; Premium sees all of it.
Unified data coverage and cross-signal highlights — market, SEC, earnings, opportunity
Strengthen intelligence
Prior close
$58.21
Market cap
$22.59B
Profitable
Yes
Revenue $674.14M
Net income
$17.88M
FY Sep 22, 2026
Loading Wall Street consensus…
Loading earnings intelligence…
Building technical intelligence snapshot — check back shortly.
Loading market context…
No price history. Sync market data to load charts.
Loading SEC filing intelligence…
No filings ingested yet.
Investment Snapshot above is the primary AlphaOS analysis for Royalty Pharma plc — structured signals and evidence from proprietary pipelines, not an encyclopedia overview.
Research & analysis only — not investment advice. Price, charts, and filings are above.
Follow Royalty Pharma plc through AlphaOS's knowledge graph — themes, peers, beneficiaries, earnings, and research answers.
Connected companies and research pages from the AlphaOS knowledge graph.
Structured stock intelligence for companies connected to this research.